





Polycythemia

Objectives:

-To understand the meaning of myeloproliferative neoplasm (MPN) and its clinical presentation.

-To differentiate between primary and secondary polycythemia.

-To obtain an overview about primary myelofibrosis and essential thrombocythemia.

-To appreciate the importance of genetic abnormalities (clonality) in these hematological neoplasms and the idea of targeted therapy.

References:

Editing file



Important.

Extra.

Notes

436 girls & boys' slides 435 teamwork slides


Do you have any suggestions? Please contact us!



@haematology436

E-mail: Haematology436@gmail.com

or simply use this <u>form</u>



قبل بدايتك في المحاضرة ننصحك بمشاهدة هذا الفيديو من عمل التيم فيه شرح عام للمحاضرة ممكن يسهل عليك




Myeloproliferative neoplasm (MPN) features:

- •Cytosis.
- Organomegaly (mainly splenomegaly).
- High uric acid. Because of increased turnover of these cells may cause gout
- Hypercellular bone marrow.
- Clonal evolution.
- Progression to acute leukemia ,mainly (Acute Myeloid Leukemia).

Myeloproliferative neoplasm (MPN) is a group of interacting diseases where bone marrow stem cells are affected (by an acquired abnormality) which result in **increase proliferation** It can affect any cell lineage:

- When red cells' precursor is affected \leftarrow polycythemia Vera
- When platelets are affected \leftarrow essential thrombocytosis
- When all three lineages are affected ← primary myelofibrosis



Relationship between the three myeloproliferative diseases. They may all arise by somatic mutation in the pluripotential stem and progenitor cells. Many transitional cases occur showing features of two conditions and, in other cases, the disease transforms during its course from one of these diseases to another or to acute myeloid leukaemia. The three diseases, polycythaemia rubra vera, essential thrombocythaemia and primary myelofibrosis, are characterized by *JAK2* or *CALR* mutation in a varying proportion of cases.


Polycythemia

- In Greek, "too many cells in the blood.".
- Absolute increase in total body red cell volume (or mass).
- Manifests itself as a raised hemoglobin or packed cell volume (PCV), maybe


masked by other disorders like iron deficiency.

• Almost always, accompanied with <u>IAK2 mutation</u>.

Regulation of Erythropoiesis by erythropoietin: مشروحة في الفيديو



Calcification of polycythemia. Important! مشروحة في الفيديو



2ry polycythemia: Any cause that interrupt with EPO production or affect kidneys may cause more RBCs and this is not a clonal disease

Polycythemia vera:

It is a type of MPN characterized by increased red blood cell production independent of the mechanisms that normally regulate erythropoiesis (intrinsic proliferation and anti-apoptotic).

Diagnostic features of polycythemia vera:

- HB >16.5g/dl in men, 16.0g/dl in women. (raised Hb).
- Hypercellular bone marrow (pan-myelosis all myelo cell lineages may be increased).
- JAK2 mutation in >95% of cases.
- No increase in serum erythropoietin level. Because it is not the cause.

Clinical feature of polycythemia vera :

<u>1-Increased blood viscosity</u> due to increase the number of RBCs related to plasma.

- Hypertension
- Headache, dizziness, visual disturbances & paresthesia
- pruritus.

2- Thrombosis

- Deep vein thrombosis
- Myocardial infarction
- Mesenteric, portal or splenic vein thrombosis

<u>3-Splenomegaly in 70%</u> most important feature due to Extra destruction of RBCs in the

spleen, because of its high number

<u>4-Hepatomegaly in 40%</u>

When do we say that this patient has PV? Important!

• When he has 3 Major criteria or First 2 Major and the Minor criteria.

- Major criteria

- 1. Hb> 16.5 g/dl in men or Hb>16.0 g/dl in women Or Hematocrit > 49% in men or >48% in women
- Or Increased Red Cells Mass (RCM).
- 2. Bone Marrow biopsy shows (panmyelosis).
- 3. Presence of JAK2V617 or JAK2 exon12 Mutation.

Investigations of polycythemia vera :

CBC:


*RBC: increased *Hb: increased

*WBC&PLT (platelets) :mildly increased (usually). <u>Blood smear:</u>

- Excess of normocytic normochromic RBC.
- ± Leukocytosis &thrombocytosis.


Bone marrow


- Hypercellular.
- Predominant erythroid precursors.
- ± Increased megakaryocytes & myeloid precursors.





 Subnormal serum erythropoietin level.






Complication and treatment of polycythemia vera:

Treatment: Not important

- Venesectiont+ Aspirin to prevent thrombosis
- ± Myelo-suppressive drugs (hydroxyurea) it's a chemotherapy

Complications:



Primary myelofibrosis


- It is a clonal MPN characterized by a proliferation of megakaryocytes & granulocytes in the bone marrow that associated with deposition of fibrous connective tissue and extramedullary hematopoiesis
- Clinical feature of primary myelofibrosis :

•Anemia

• Leukoerythroblastic blood picture. Due to bone marrow stress from fibrosis


• Massive splenomegaly. (The bone marrow is filled with fibrosis so extramedullary hematopoiesis is required and splenomegally is massive because the spleen not only filter but also makes new cells so even bigger than in polycythemia Vera or Essential thrombocythemia)

- Fibrotic bone marrow.
- JAK2 mutation (50%-60%).
- Risk of AML transformation (10-20%).




دهمة ومشروحة في الفيديو.Elast cells seen in peripheral blood because bone marrow is filled with fibrosis - Nucleated RBCs (immature) -Blast WBS -Tear drop cells

Bone marrow in myelofibrosis



Stages of primary myelofibrosis :



Essential Thrombocythemia

- It is a MPN that involves primarily the megakaryocytic lineage and characterized by sustained thrombocytosis
- Diagnostic features of Essential Thrombocythemia • Sustained thrombocytosis ≥450×10⁹/L.
 - Hypercellular BM with megakaryocytic proliferation.
 - Exclusion of: CML, MDS, PV & PMF. (all these diseases can cause thrombocytosis so exclude them) remember CML is excluded by a negative BCR-ABL
 - JAK2 V617F mutation (50-60%), CARL or MPL mutations, If negative; no evidence of reactive thrombocytosis which is : Iron deficiency, splenectomy, surgery, infection ,autoimmune

disease.... The causes of reactive thrombocytosis should be also excluded because they increase thrombocytes as well

Clinical presentation of essential thrombocytopenia

- Asymptomatic (50%)
- Thrombosis
- Bleeding (defective function of platelets)
- Mild splenomegaly (50%)
- Mild hepatomegaly (20%)


JAK2 mutation

JAK2: (Ch 9p with 26 exons), a non-receptor protein tyrosine kinase involved in signal transduction pathway.


Very indolent

(5% risk of AML

transformation)




modulating of Gene expression To start the proliferation.









Summary

The video in slide 2 summarizes everything.

MCQs:

•Which ONE of the following is NOT a cause of polycythemia?

A) Mutation of JAK-2.

B) Renal disease.

C) Congenital heart disease.

D) Hemoglobin abnormality.

E) Iron overload.

•Which ONE of these statements is TRUE about pseudo (stress) polycythemia?

A) It is caused by a raised red cell mass.

B) It is associated with a large spleen.

C) It is treated with hydroxycarbamide (hydroxyurea).

D) It is most common in young male adults.

•What is the approximate frequency of the Val617Phe mutation in *JAK2* in myeloproliferative neoplasms?

A) 99% in polycythemia vera (PV) and 50% in essential thrombocythemia (ET) and primary myelofibrosis (PM).

B) Approximately 50% in PV, ET and PM.

C) 50% in PV and 25% in ET and PM.	A	(8
D) 90% in PV, rare in ET and PM.	4	(I (1
	SMGLS	suA

Good Luck!

Team Members

Khalid Al-Husainan Abdullah Al-Nasser Dania AlKelabi Team Leaders Abdulaziz Al-Hussainy Safa Al-Osaimi